Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Autores de IIS La Fe

• Jordi Tortosa Carreres

  Autor

• Laura Cubas Núñez

  Autor

• Mónica Piqueras Rodríguez

  Autor

• Jéssica Castillo Villalba

  Autor

• Carlos Quintanilla Bordas

  Autor

• Raquel Gasque Rubio

  Autor

• Lorena Forés Toribio

  Autor

• Sara Carratalà Boscà

  Autor

• Bonaventura Casanova Estruch

  Autor

• María Begoña Laiz Marro

  Autor

• Francisco Carlos Pérez Miralles

  Autor

Participantes ajenos a IIS La Fe

• Quiroga-Varela A
• Villarrubia N
• Monreal E
• Álvarez G
• Lucas C
• Sanz MT
• Ramió-Torrentà L
• Villar LM

Grupos

• Infecciones Respiratorias

• Investigación en Neuroinmunología y Esclerosis Múltiple

Abstract

Immunohistochemical studies have identified complement component C1q in MS lesions. We aimed to compare serum (sC1q) and CSF (csfC1q) levels in a large cohort of MS patients (pwMS) (n = 222) with those of healthy controls (HC, n = 52), individuals with other immune (IND, n = 14), and non-immune neurological disorders (nIND, n = 15), and to analyze their correlation with other biomarkers. pwMS were divided into three series based on their origin. CSF samples were unavailable for HC. All three pwMS cohorts had lower sC1q levels compared to HC and IND. csfC1q was higher in one pwMS cohort, with a trend in another, and correlated with IgG, Free Kappa Light Chains, GFAP, and Chitinase-3 Like Protein-1 in CSF. Our findings suggest a significant role for C1q in MS pathophysiology, potentially serving as a biomarker for disease identification.

Copyright © 2024 Elsevier B.V. All rights reserved.

Keywords

• Biomarkers; C1q; Complement system; Disease activity; Multiple sclerosis